| Literature DB >> 26131602 |
Ze-Peng Du1, Bing-Li Wu2, Xuan Wu1, Xuan-Hao Lin1, Xiao-Yang Qiu1, Xiao-Fen Zhan1, Shao-Hong Wang1, Jin-Hui Shen1, Chun-Peng Zheng3, Zhi-Yong Wu3, Li-Yan Xu4, Dong Wang5, En-Min Li2.
Abstract
The lipocalin proteins (lipocalins) are a large family of small proteins characterized by low sequence similarity and highly conserved crystal structures. Lipocalins have been found to play important roles in many human diseases. For this reason, a systemic analysis of the molecular properties of human lipocalins is essential. In this study, human lipocalins were found to contain four structurally conserved regions (SCRs) and could be divided into two subgroups. A human lipocalin protein-protein interaction network (PPIN) was constructed and integrated with their expression data in esophageal carcinoma. Many lipocalins showed obvious co-expression patterns in esophageal carcinoma. Their subcellular distributions also suggested these lipocalins may transfer signals from the extracellular space to the nucleus using the pathway-like paths. These analyses also expanded our knowledge about this human ancient protein family in the background of esophageal carcinoma.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26131602 PMCID: PMC4487233 DOI: 10.1038/srep12010
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Human lipocalins.
| Official Symbol | Official Full Name | GeneID | Chromosome Location |
|---|---|---|---|
| AMBP | alpha-1-microglobulin/bikunin precursor | 259 | 9q32-q33 |
| APOD | apolipoprotein D | 347 | 3q29 |
| APOM | apolipoprotein M | 55937 | 6p21.33 |
| C8G | complement component 8, gamma polypeptide | 733 | 9q34.3 |
| CRABP1 | cellular retinoic acid binding protein 1 | 1381 | 15q24 |
| CRABP2 | cellular retinoic acid binding protein 2 | 1382 | 1q21.3 |
| FABP1 | fatty acid binding protein 1, liver | 2168 | 2p11 |
| FABP12 | fatty acid binding protein 12 | 646486 | 8q21.13 |
| FABP2 | fatty acid binding protein 2, intestinal | 2169 | 4q28-q31 |
| FABP3 | fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) | 2170 | 1p33-p32 |
| FABP4 | fatty acid binding protein 4, adipocyte | 2167 | 8q21 |
| FABP5 | fatty acid binding protein 5 (psoriasis-associated) | 2171 | 8q21.13 |
| FABP6 | fatty acid binding protein 6, ileal | 2172 | 5q33.3-q34 |
| FABP7 | fatty acid binding protein 7, brain | 2173 | 6q22-q23 |
| FABP9 | fatty acid binding protein 9, testis | 646480 | 8q21.13 |
| LCN1 | lipocalin 1 | 3933 | 9q34 |
| LCN10 | lipocalin 10 | 414332 | 9q34.3 |
| LCN12 | lipocalin 12 | 286256 | 9q34.3 |
| LCN15 | lipocalin 15 | 389812 | 9q34.3 |
| LCN1P1 | lipocalin 1 pseudogene 1 | 286310 | 9q34.2 |
| LCN2 | lipocalin 2 | 3934 | 9q34 |
| LCN6 | lipocalin 6 | 158062 | 9q34.3 |
| LCN8 | lipocalin 8 | 138307 | 9q34.3 |
| LCN9 | lipocalin 9 | 392399 | 9q34.3 |
| LCNL1 | lipocalin-like 1 | 401562 | 9q34.3 |
| OBP2A | odorant binding protein 2A | 29991 | 9q34 |
| OBP2B | odorant binding protein 2B | 29989 | 9q34 |
| ORM1 | orosomucoid 1 | 5004 | 9q32 |
| ORM2 | orosomucoid 2 | 5005 | 9q32 |
| PAEP | progestagen-associated endometrial protein | 5047 | 9q34 |
| PMP2 | peripheral myelin protein 2 | 5375 | 8q21.3-q22.1 |
| PTGDS | prostaglandin D2 synthase 21kDa (brain) | 5730 | 9q34.2-q34.3 |
| RBP1 | retinol binding protein 1, cellular | 5947 | 3q23 |
| RBP2 | retinol binding protein 2, cellular | 5948 | 3q23 |
| RBP4 | retinol binding protein 4, plasma | 5950 | 10q23.33 |
| RBP5 | retinol binding protein 5, cellular | 83758 | 12p13.31 |
| RBP7 | retinol binding protein 7, cellular | 116362 | 1p36.22 |
Figure 1(A) Protein sequence alignment of human lipocalins. The four structurally conserved regions (SCRs) are indicated in four blocks. (B) Cluster of sequence similarities, indicating human lipocalins could be divided into two subgroups.
Figure 2Functional categories of the lipocalins were visualized using the Enrichment map plugin of the Cytoscape.
Significant functional terms are represented by one node with its size indicating the significance of the enrichment (P-value). Edges indicate gene overlap between nodes and thickness indicates the number of overlapping enriched genes.
Figure 3(A-B) The human lipocalin protein-protein interaction network and the lipocalins’ changes in expression in esophageal adenocarcinoma and esophageal squamous cell carcinoma are shown. The lipocalins are shown using triangles, and their interacting proteins are shown in circles. Red indicates upregulation and green indicates downregulation. The size of the node indicates the degree (the number of its interacting proteins) of the node. Bigger nodes have higher degrees. The connection between two nodes is indicated by an edge. Red edges indicate positive correlations in the expression of two proteins, and green edges indicate negative correlations. Correlation strength is shown by the edge width. (C) Expression levels of lipocalins in esophageal adenocarcinoma and esophageal squamous cell carcinoma. (D) The power law distribution of the node degree network and analysis of other network parameters. (E) Functional map of the lipocalins PPIN. Functionally grouped network with GO terms are represented as nodes, which were linked based on their kappa score level (≥0.3), suggesting overlapped enriched genes. The similar GO terms were labeled in the same color.
Figure 4Co-expression patterns of lipocalins in esophageal adenocarcinoma and esophageal squamous cell carcinoma.
Significant correlations in the expression of lipocalins in esophageal carcinoma.
| EAC | ESCC | ||
|---|---|---|---|
| Lipocalin | Highly co-expressed lipocalins | lipocalin | Highly co-expressed lipocalins |
| C8G | CRABP1, LCN1, FABP4, PAEP OBP2B, LCN15, PMP2, OBP2A, ORM1, RBP5, LCN6, FABP7 | OBP2B | LCN1, PAEP, OBP2A; LCN8, LCN1, LCN15, LCNL1, CRABP1, RBP5, ORM1 |
| CRABP1 | C8G, LCN1, FABP4, PAEP OBP2B, LCN15, PMP2, OBP2A, ORM1, RBP5, LCN6, FABP7, LCNL1, LCN8, FABP3 | LCN1 | PAEP, OBP2A; LCN8, OBP2B, LCN1, LCN15, LCNL1, CRABP1, RBP5, ORM1 |
| LCN1 | FABP4, PAEP OBP2B, LCN15, PMP2, OBP2A, ORM1, RBP5, LCN6, LCN12, FABP7, LCNL1, LCN8, FABP3, RBP2 | PAEP | OBP2A; LCN8, OBP2B, LCN1, LCN15, LCNL1, CRABP1, RBP5, ORM1 |
| FABP4 | PAEP, OBP2B, LCN15, PMP2, OBP2A, ORM1, RBP5, PMP2, OBP2A, ORM1, RBP5, LCN6, LCN12, FABP7, LCNL1, FABP3 | OBP2A | LCN8, OBP2B, LCN1, LCN15, LCNL1, PAEP, CRABP1, RBP5, ORM1 |
| PAEP | C8G, LCN1, FABP4, PAEP OBP2B, LCN15, PMP2, OBP2A, ORM1, RBP5, FABP7, LCNL1, FABP3 | LCNL1 | PAEP: OBP2A; LCN8, OBP2B, LCN1, LCN15, CRABP1, RBP5 |
| LCN8 | OBP2B, LCN1, LCN15, LCNL1, PAEP, OBP2A, RBP5 | ||
| LCN2 | RBP4, APOD | ||
Figure 5(A) Subcellular layers illustrating the lipocalins PPIN. (B) 20 possible paths from LCN2 to RB1 with integrated with their subcellular localization.
Possible signal pathways from LCN2 to RB1.
| No. | Proteins of the path | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LCN2 | → | HGF | → | FN1 | → | RBBP4 | → | RB1 |
| 2 | LCN2 | → | HGF | → | FN1 | → | SUMO2 | → | RB1 |
| 3 | LCN2 | → | HGF | → | FN1 | → | HDAC1 | → | RB1 |
| 4 | LCN2 | → | HGF | → | FN1 | → | UBC | → | RB1 |
| 5 | LCN2 | → | LRP2 | → | RBP1 | → | SIRT1 | → | RB1 |
| 6 | LCN2 | → | LRP2 | → | RBP1 | → | RBBP7 | → | RB1 |
| 7 | LCN2 | → | LRP2 | → | RBP1 | → | HDAC2 | → | RB1 |
| 8 | LCN2 | → | LRP2 | → | APP | → | MORF4L1 | → | RB1 |
| 9 | LCN2 | → | LRP2 | → | APP | → | PPARG | → | RB1 |
| 10 | LCN2 | → | LRP2 | → | APP | → | CCND3 | → | RB1 |
| 11 | LCN2 | → | LRP2 | → | RBP1 | → | RBBP4 | → | RB1 |
| 12 | LCN2 | → | LRP2 | → | RBP1 | → | HDAC1 | → | RB1 |
| 13 | LCN2 | → | LRP2 | → | APP | → | UBC | → | RB1 |
| 14 | LCN2 | → | LRP2 | → | SERPINE1 | → | UBC | → | RB1 |
| 15 | LCN2 | → | LRP2 | → | ALB | → | UBC | → | RB1 |
| 16 | LCN2 | → | LRP2 | → | RBP1 | → | UBC | → | RB1 |
| 17 | LCN2 | → | MMP9 | → | FN1 | → | RBBP4 | → | RB1 |
| 18 | LCN2 | → | MMP9 | → | FN1 | → | SUMO2 | → | RB1 |
| 19 | LCN2 | → | MMP9 | → | FN1 | → | HDAC1 | → | RB1 |
| 20 | LCN2 | → | MMP9 | → | FN1 | → | UBC | → | RB1 |